---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103058"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:36:44.459203+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance

## Summary
- Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.
- clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).
- Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.
- FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.
- Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue.

## SEC filing metadata
- accession: 0000950170-25-103058
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/0000950170-25-103058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/adpt-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103058
- JSON: https://secwatch.observer/filing/0000950170-25-103058.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.